Please use this identifier to cite or link to this item:
|Title:||Small lipidated anti-obesity compounds derived from neuromedin U|
|Authors:||Micewicz, E. D.|
Bahattab, O. S.
Willars, Gary Brian
Waring, A. J.
Whitelegge, J. P.
McBride, W. H.
|Publisher:||Elsevier, French Société de Chimie Thérapeutique (SCT)|
|Citation:||European Journal of Medicinal Chemistry, 2015, 101, pp. 616-626|
|Abstract:||A small library of truncated/lipid-conjugated neuromedin U (NmU) analogs was synthesized and tested in vitro using an intracellular calcium signaling assay. The selected, most active analogs were then tested in vivo, and showed potent anorexigenic effects in a diet-induced obese (DIO) mouse model. The most promising compound, NM4-C16 was effective in a once-weekly-dose regimen. Collectively, our findings suggest that short, lipidated analogs of NmU are suitable leads for the development of novel anti-obesity therapeutics.|
|Rights:||Copyright © 2015, Elsevier Masson SAS. All rights reserved. This manuscript version is made available after the end of the embargo period under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/|
|Description:||The file associated with this record is under a 24-month embargo from publication in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.|
|Appears in Collections:||Published Articles, College of Medicine, Biological Sciences and Psychology|
Files in This Item:
|2015 EJMC pre-pub.pdf||Post-review (final submitted)||1.5 MB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.